Trial Profile

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS-209 (Primary)
Indications Hereditary nonpolyposis colorectal cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

16 Jan 2026 According to Nouscom media release, data from the trial were presented in Nature Medicine
16 Jan 2026 Results presented in the Nouscom Media Release
07 Nov 2025 According to Nouscom media release, company announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com